Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts

Thierry Tiendrebeogo; Karen Malateste; Armel Poda; Albert Minga; Eugene Messou; Henri Chenal; Oliver Ezechi; Didier K Ekouevi; Igho Ofotokun; Antoine Jaquet; IeDEA West Africa Collaboration

doi:10.1093/ofid/ofae139

Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts

Open Forum Infect Dis. 2024 Mar 19;11(5):ofae139. doi: 10.1093/ofid/ofae139. eCollection 2024 May.

Authors

Collaborators

IeDEA West Africa Collaboration:
Marcel Djimon Zannou, Armel Poda, Oliver Ezechi, Eugene Messou, Henri Chenal, Kla Albert Minga, Aristophane Tanon, Moussa Seydi, Ephrem Mensah, Caroline Yonaba, Lehila Bagnan Tossa, Jocelyn Dame, Sylvie Marie N'Gbeche, Kouadio Kouakou, Madeleine Amorissani Folquet, François Tanoh Eboua, Fatoumata Dicko Traore, Agatha David, Elom Takassi, Antoine Jaquet, Didier Koumavi Ekouevi, François Dabis, Renaud Becquet, Charlotte Bernard, Karen Malateste, Olivier Marcy, Marie Kerbie Plaisy, Elodie Rabourdin, Thierry Tiendrebeogo, Désiré Dahourou, Sophie Desmonde, Julie Jesson, Valeriane Leroy, Raoul Moh, Jean-Claude Azani, Jean Jacques Koffi, Eric Komena, Maika Bengali, Abdoulaye Cissé, Guy Gnepa, Apollinaire Horo, Simon Boni, Eulalie Kangah, Corinne Moh, Jeanne Eliam, Ighovwerha Ofotokun, Chris Martin, Noelle Benzekri, Geoffrey Goettlieb, Olivia Keiser, Antoine Jaquet, Didier Ekouevi, Ighovwerha Ofotokun, Renaud Becquet, Noelle Benzekri, Charlotte Bernard, Simon Boni, François Dabis, Désiré Dahourou, Sophie Desmonde, Didier Koumavi Ekouevi, Antoine Jaquet, Julie Jesson, Eric Komena, Valeriane Leroy, Karen Malateste, Ighovwerha Ofotokun, Marie Kerbie Plaisy, Elodie Rabourdin, Thierry Tiendrebeogo

Affiliations

¹ National Institute for Health and Medical Research UMR 1219, Research Institute for Sustainable Development EMR 271, Bordeaux Population Health Research Centre, University of Bordeaux, Bordeaux, France.
² Department of Infectious Diseases, Université Nazi Boni, Bobo-Dioulasso, Burkina Faso.
³ Centre médical de Suivi des Donneurs de Sang, Centre National de Transfusion Sanguine Côte d'Ivoire, Abidjan, Côte d'Ivoire.
⁴ Centre de Prise en charge de Recherche et de Formation, Abidjan, Côte d'Ivoire.
⁵ Programme PACCI/ANRS Research Center, Abidjan, Cote d'Ivoire.
⁶ Département de Dermatologie et d'Infectiologie, Unite de Formation et de Recherche des Sciences Médicales, Université Félix Houphouët Boigny, Abidjan, Côte d'Ivoire.
⁷ Virology Laboratory, Integrated Centre for Bioclinical Research in Abidjan, Abidjan, Côte d'Ivoire.
⁸ Office of the Central Secretariat, Nigeria Institute for Medical Research, Lagos, Nigeria.
⁹ Département de Santé Publique, Université de Lomé, Lomé, Togo.
¹⁰ Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.

Abstract

Transition to dolutegravir among 21 167 individuals experienced in antiretroviral therapy in West Africa showed heterogeneous timelines and patterns. Initially reported sex disparities tended to catch up over time with persisting disparities, according to contributing HIV clinics. Key factors facilitating dolutegravir switch were male sex, age <50 years, viral suppression, and regimens not based on protease inhibitors.

Keywords: HIV; West Africa; dolutegravir; sex disparities; switch.

Grants and funding

U01 AI069919/AI/NIAID NIH HHS/United States